From: Predicting and characterizing selective multiple drug treatments for metabolicdiseases and cancer
# | Drugs | Side effect |
---|---|---|
1 | Floxuridine (# 20) | 1 |
2 | Mycophenolic acid (# 42) | 4 |
3 | Trimethoprim (# 29) | 5 |
4 | Methotrexate (# 11) | 5 |
5 | Atovaquone (# 69) | 6 |
6 | Tyloxapol (# 85) | 6 |
7 | Ezetimibe (# 56) | 12 |
8 | Pemetrexed (# 41) | 15 |
9 | Ribavirin (# 51) | 17 |
10 | Quinacrine (# 36) | 22 |
11 | Myo-Inositol (# 82) | 29 |
12 | Tioconazole (# 60) | 34 |
13 | Naftifine (# 43) | 34 |
14 | Simvastatin (# 4) | 42 |
15 | Leflunomide (# 66) | 42 |
16 | Auranofin (# 59) - Fomepizole (# 75) | 47 |
17 | Indomethacin (# 22) | 48 |
18 | Diclofenac (# 35) | 55 |
19 | Hydroxyurea (# 16) | 56 |
20 | Arsenic trioxide (# 72) | 56 |
21 | Gemcitabine (# 30) | 99 |